Asociación de Laboratorios Clínicos v. Triple-S Advantage Inc. et al.

CourtDistrict Court, D. Puerto Rico
DecidedMay 4, 2026
Docket3:26-cv-01013
StatusUnknown

This text of Asociación de Laboratorios Clínicos v. Triple-S Advantage Inc. et al. (Asociación de Laboratorios Clínicos v. Triple-S Advantage Inc. et al.) is published on Counsel Stack Legal Research, covering District Court, D. Puerto Rico primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Asociación de Laboratorios Clínicos v. Triple-S Advantage Inc. et al., (prd 2026).

Opinion

THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF PUERTO RICO

Asociación de Laboratorios Clínicos, Plaintiffs, Civ. No. 26-01013 (MAJ) v.

Triple-S Advantage Inc. et al., Defendants.

OPINION AND ORDER I. Introduction On December 1, 2025, Asociación de Laboratorios Clinicos, Inc. (“Plaintiff”) filed this declaratory judgment action against Triple-S Advantage, Inc. and Triple-S Salud, Inc. (“Defendants”) in state court. (ECF No. 1 at 1 ¶ 1). Plaintiff is a non-profit entity that represents an association of clinical laboratories in Puerto Rico. (ECF No. 1-1 at 1–2 ¶¶ 2–5). Defendants are affiliated insurance companies that provide health care insurance under the federal Medicare Advantage program. (ECF No. 1-1 at 2 ¶ 6). The Complaint alleges that Plaintiff’s members each hold a contract with Defendants for the provision of laboratory services to individuals insured by Defendants. (ECF No. 1-1 at 3 ¶¶ 9–10). At issue in this litigation is a contractual term that set the “fee schedule” controlling the payments due from Defendants to Plaintiff’s members for the provision of services to covered patients. (ECF No. 10-1 at 5); (ECF No. 1-1 at 4 ¶ 14). The contractual term in dispute reads as follows: “Fee Schedule” shall mean the schedule of the maximum payment amount to be paid under this Agreement by Triple-S to the Provider for the provision of Covered Services to Members, which amount shall be the lesser of the following: a. the applicable Medicare Fee Schedule published by CMS, subject to any subsequent changes to the Medicare Fee Schedule, as amended from time to time; or b. the actual fees or charges billed by the Provider; or c. the contracted amount. (ECF No. 10-1 at 5). Elsewhere, the contract also provided that “applicable fees . . . shall be subject to amendments provisions and notice requirements” and that Defendants retained the right to “amend [the] Agreement without the need to execute either an Addendum . . . or an Amended and Restated Agreement.” (ECF No. 10-1 at 10, 37). At the time that the contract was executed, an attachment to the contract provided that applicable Medicare Fee Schedule rates would be equal to a set percentage of the 2016 Medicare Fee Schedule published by the Centers for Medicare and Medicaid Services (“CMS”). (ECF No. 1-1 at 3 ¶ 12); (ECF No. 10-1 at 44). On May 23, 2025, Defendants notified Plaintiff’s members that the fee schedule governing their agreement would be adjusted to a fixed percentage of the prices set by the 2025 Medicare Fee Schedule. (ECF No. 1-1 at 4 ¶ 14); (ECF No. 10-2). The resulting fee schedule established reimbursement rates less than those set under the previously applicable Medicare Fee Schedule. (ECF No. 1-1 at 4 ¶ 15). Plaintiff alleges that the reduced rates are not sufficient to cover the costs of the medical services performed by its members. (ECF No. 1-1 at 4 ¶ 16). To contest the new fee schedule, Plaintiff filed the instant action before the Court of First Instance of Puerto Rico. The Complaint invokes Article 1249 of the Puerto Rico Civil Code, which renders voidable any contractual clause that authorizes unilateral modifications to the terms of a contract of adhesion. (ECF No. 1-1 at 4 ¶ 18, 9 ¶ 32) (citing 31 L.P.R.A. § 9803). The Complaint does not set forth any additional claims.

II. Procedural Background On January 9, 2026, Defendants filed a Notice of Removal, removing this case to federal court. (ECF No. 1) (citing 28 U.S.C. § 1441 (“Removal of civil actions”)). Defendants assert federal question jurisdiction under 28 U.S.C. Section 1331, which authorizes federal district courts to hear civil actions “arising under the Constitution, laws or treaties of the United States.” (ECF No. 1 at 4 ¶ 13). On February 9, 2026, Plaintiff filed a motion to remand this case to local court, arguing that this Court lacks jurisdiction

to entertain the case. (ECF No. 9). Plaintiff argues that this Court lacks subject matter jurisdiction over the action and removal was improper because the parties are non- diverse and the sole claim alleged in the Complaint arises under state law. Defendants oppose the motion. (ECF No. 13).1 Defendants do not dispute that the parties are non-diverse or that the Complaint does not expressly present a claim that arises under federal law. Instead, Defendants invoke the so-called “federal ingredient” doctrine, which “permits removal of a well pleaded claim sounding in state law which necessarily requires resolution of a substantial question of federal law.” Metheny v.

Becker, 352 F.3d 458, 460 (1st Cir. 2003) (quoting Franchise Tax Bd. v. Construction Laborers Vacation Trust, 463 U.S. 1, 13 (1983) (internal quotations omitted)). Specifically, Defendants argue that the relief Plaintiffs seek would effectively “void

1 Plaintiff filed a reply brief, (ECF No. 19), and Defendant filed a sur-reply, (ECF No. 22). Defendants’ lawful use of the current . . . Medicare Fee Schedule” promulgated by CMS. (ECF No. 13 at 4).

III. Analysis The “federal ingredient” doctrine holds that original federal jurisdiction may be established “where, regardless of whether federal or state law creates the claim, a well- pleaded complaint necessarily requires resolution of a substantial question of federal law.” Almond v. Capital Properties, Inc., 212 F.3d 20, 23 (1st Cir. 2000) (internal quotations and citations omitted). Thus, even where no federal law creates the cause of action asserted, federal jurisdiction may lie in a “special and small category of cases”

where a state-law claim necessarily raises an “embedded federal question,” such that “a federal forum may entertain [the claim] without disturbing the congressionally approved balance of federal and state judicial responsibilities.” Industria Lechera de Puerto Rico, Inc. v. Beiró, 989 F.3d 116, 121 (1st Cir. 2021) (internal quotations and citations omitted). In order to serve as a proper basis for federal jurisdiction, the embedded federal ingredient must be (1) necessarily raised, (2) actually disputed, (3) substantial, and (4) capable of resolution without disrupting the federal-state balance created by Congress. Gunn v. Minton, 568 U.S. 251, 258 (2013).

Such cases where “a federal issue is [so] decisive” that a federal court may entertain a suit arising from state law between non-diverse parties are “rare.” One and Ken Valley Housing Group v. Maine State Housing Authority, 716 F.3d 218, 224 (1st Cir. 2026). “The Supreme Court has periodically affirmed this basis for jurisdiction in the abstract[,] . . . occasionally cast doubt upon it, rarely applied it in practice, and left the very scope of the concept unclear.” Almond, 212 F.3d at 23. “Perhaps the best one can say[,]” the First Circuit has summarized, “is that this basis [for jurisdiction] endures in principle but should be applied with caution and various qualifications.” Id.

Defendants argue that this case presents a substantial, actually disputed, and necessarily raised “federal ingredient” that may be litigated in federal court without disrupting the federal-state balance created by Congress because “Medicare Advantage standards expressly preempt state law[.]” (ECF No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Skelly Oil Co. v. Phillips Petroleum Co.
339 U.S. 667 (Supreme Court, 1950)
Metropolitan Life Insurance v. Taylor
481 U.S. 58 (Supreme Court, 1987)
Caterpillar Inc. v. Williams
482 U.S. 386 (Supreme Court, 1987)
Metheny v. Becker
352 F.3d 458 (First Circuit, 2003)
Fayard v. Northeast Vehicle Services, LLC
533 F.3d 42 (First Circuit, 2008)
Gunn v. Minton
133 S. Ct. 1059 (Supreme Court, 2013)
Medical Card System, Inc. v. Equipo Pro Convalecencia
587 F. Supp. 2d 384 (D. Puerto Rico, 2008)
Hochendoner v. Genzyme Corporation
823 F.3d 724 (First Circuit, 2016)
Industria Lechera de PR v. Flores
989 F.3d 116 (First Circuit, 2021)
Colon v. Diaz
174 F. Supp. 3d 667 (D. Puerto Rico, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Asociación de Laboratorios Clínicos v. Triple-S Advantage Inc. et al., Counsel Stack Legal Research, https://law.counselstack.com/opinion/asociacion-de-laboratorios-clinicos-v-triple-s-advantage-inc-et-al-prd-2026.